Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2‐dependent mechanism

Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2‐dependent mechanism

Abstract Background N6‐methyladenosine (m6A) is of great importance in renal physiology and disease progression, but its function and mechanism in renal fibrosis remain to be comprehensively and extensively explored. Hence, this study will explore the function and potential mechanism of critical reg...

Full description

Bibliographic Details
Main Authors: Wei‐Jian Ni, Hong Zhou, Hao Lu, Nan‐Nan Ma, Bing‐Bing Hou, Wei Li, Fan‐Xu Kong, Ju‐Tao Yu, Rui Hou, Juan Jin, Jia‐Gen Wen, Tao Zhang, Xiao‐Ming Meng
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Clinical and Translational Medicine
Subjects:
chronic kidney disease
insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2)
methyltransferase‐like 3 (METTL3)
N6‐methyladenosine (m6A)
renal fibrosis
traditional Chinese medicine
Online Access:https://doi.org/10.1002/ctm2.1359

Internet

https://doi.org/10.1002/ctm2.1359

Similar Items